The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice

The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice

Objective: to evaluate the clinical efficacy and safety of the targeted synthetic disease-modifying antirheumatic drug (DMARD) apremilast (AP; Otesla®) in patients with active psoriatic arthritis (PsA) at 14 and 26 weeks after starting the treatment and to identify the place of AP in the combination...

Full description

Bibliographic Details
Main Authors: E. Yu. Loginova, Yu. L. Korsakova, A. D. Koltakova, E. E. Gubar, P. L. Karpova, S. I. Glukhova, T. V. Korotaeva
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2019-07-01
Series:Научно-практическая ревматология
Subjects:
psoriatic arthritis
comorbidity
apremilast
phosphodiesterase 4 inhibitor
remission
minimal disease activity
Online Access:https://rsp.mediar-press.net/rsp/article/view/2730

Internet

https://rsp.mediar-press.net/rsp/article/view/2730

Similar Items